Healthcare software provider Health Catalyst (NASDAQ:HCAT) reported Q1 FY2022 results that beat analyst expectations, with revenue up 21.9% year on year to $68 million. However, guidance for the next quarter was less impressive, coming in at $69.5 million at the midpoint, being 2% below analyst estimates. Health Catalyst made a GAAP loss of $22.4 million, improving on its loss of $28.3 million, in the same quarter last year.
Is now the time to buy Health Catalyst? Access our full analysis of the earnings results here, it's free.
Health Catalyst (HCAT) Q1 FY2022 Highlights:
- Revenue: $68 million vs analyst estimates of $66.0 million (3.13% beat)
- EPS (non-GAAP): -$0.06 vs analyst estimates of -$0.11
- Revenue guidance for Q2 2022 is $69.5 million at the midpoint, below analyst estimates of $70.9 million
- The company reconfirmed revenue guidance for the full year, at $290.3 million at the midpoint
- Free cash flow was negative $2.45 million, compared to negative free cash flow of $13.4 million in previous quarter
- Gross Margin (GAAP): 50%, down from 51% same quarter last year
“In the first quarter of 2022, I am pleased to share that we began the year by achieving strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA,” said Dan Burton, CEO of Health Catalyst.
Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.
Organizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the silo-ed data.
As you can see below, Health Catalyst's revenue growth has been strong over the last year, growing from quarterly revenue of $55.8 million, to $68 million.
This quarter, Health Catalyst's quarterly revenue was once again up a very solid 21.9% year on year. On top of that, revenue increased $3.37 million quarter on quarter, a solid improvement on the $2.97 million increase in Q4 2021. Happily, that's a slight re-acceleration of growth.
Guidance for the next quarter indicates Health Catalyst is expecting revenue to grow 16.5% year on year to $69.5 million, slowing down from the 37.8% year-over-year increase in revenue the company had recorded in the same quarter last year. Ahead of the earnings results the analysts covering the company were estimating sales to grow 19.9% over the next twelve months.
In volatile times like these we look for robust businesses with strong pricing power. Unknown to most investors, this company is one of the highest-quality software companies in the world, and their software products have been the default standard in critical industries for decades. The result is an impressive business that is up an incredible 18,152% since the IPO. You can find it on our platform for free.
What makes the software as a service business so attractive is that once the software is developed, it typically shouldn't cost much to provide it as an ongoing service to customers. Health Catalyst's gross profit margin, an important metric measuring how much money there is left after paying for servers, licenses, technical support and other necessary running expenses was at 50% in Q1.
That means that for every $1 in revenue the company had $0.50 left to spend on developing new products, marketing & sales and the general administrative overhead. While it improved significantly from the previous quarter this would still be considered a low gross margin for a SaaS company and we would like to see the improvements continue.
Key Takeaways from Health Catalyst's Q1 Results
Since it has still been burning cash over the last twelve months it is worth keeping an eye on Health Catalyst’s balance sheet, but we note that with a market capitalization of $698.4 million and more than $425.4 million in cash, the company has the capacity to continue to prioritise growth over profitability.
We were very impressed by the strong improvements in Health Catalyst’s gross margin this quarter. And we were also excited to see that it outperformed analysts' revenue expectations. On the other hand, it was unfortunate to see that the revenue guidance for the next quarter missed analysts' expectations. Zooming out, we think this was still a decent, albeit mixed, quarter, showing the company is staying on target. But investors might have been expecting more and the company is down 0.73% on the results and currently trades at $12.85 per share.
Should you invest in Health Catalyst right now? It is important that you take into account its valuation and business qualities, as well as what happened in the latest quarter. We look at that in our actionable report which you can read here, it's free.
One way to find opportunities in the market is to watch for generational shifts in the economy. Almost every company is slowly finding itself becoming a technology company and facing cybersecurity risks and as a result, the demand for cloud-native cybersecurity is skyrocketing. This company is leading a massive technological shift in the industry and with revenue growth of 70% year on year and best-in-class SaaS metrics it should definitely be on your radar.
The author has no position in any of the stocks mentioned.